https://crstodayeurope.com/news/aao-honors-leaders-in-medical-and-surgical-eye-care/2476997/daily0.7https://crstodayeurope.com/news/optos-unveils-silverstone-combined-ultra-widefield-retinal-imaging-device-and-uwf-guided-swept-source-oct/2476998/daily0.7https://crstodayeurope.com/news/norlase-enters-ophthalmic-market-with-launch-of-leaf-ultra-compact-green-laser-photocoagulator/2476999/daily0.7https://crstodayeurope.com/news/cataract-surgery-can-make-you-48-percent-safer-on-the-road/2477000/daily0.7https://crstodayeurope.com/news/zeiss-showcases-new-digital-technologies-and-diagnostics-at-aao/2477001/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-announces-new-data-products-and-physician-resources-at-aao-2019/2476994/daily0.7https://crstodayeurope.com/news/glaukos-achieves-pipeline-milestone-with-completion-of-patient-enrollment-in-us-ide-trial-for-istent-infinite/2476990/daily0.7https://crstodayeurope.com/news/aerpio-pharmaceuticals-announces-interim-results-from-its-phase-1b-clinical-trial-of-akb-9778-for-primary-open-angle-glaucoma/2476991/daily0.7https://crstodayeurope.com/news/harbour-biomed-announces-completion-of-phase-2-study-in-china-of-hbm9036-in-patients-with-moderate-to-severe-dry-eye-disease/2476993/daily0.7https://crstodayeurope.com/news/new-data-from-teprotumumab-phase-3-study-shows-significantly-reduced-double-vision-for-people-with-active-thyroid-eye-disease/2476988/daily0.7https://crstodayeurope.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/daily0.7https://crstodayeurope.com/news/esight-3-approved-on-the-us-department-of-veterans-affairs-va-federal-supply-schedule/2476985/daily0.7https://crstodayeurope.com/news/worlds-leading-eye-physicians-and-surgeons-gather-in-san-francisco-to-inspire-the-future-of-eye-care/2476986/daily0.7https://crstodayeurope.com/news/alcon-celebrates-world-sight-day-strengthens-commitment-to-enhancing-global-access-to-eye-care/2476983/daily0.7https://crstodayeurope.com/news/on-world-sight-day-allergan-launches-national-campaign-to-raise-awareness-of-glaucoma/2476984/daily0.7https://crstodayeurope.com/news/teclens-announces-completion-of-enrollment-of-a-pilot-clinical-study-for-the-treatment-of-keratoconus/2476980/daily0.7https://crstodayeurope.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/daily0.7https://crstodayeurope.com/news/for-world-sight-day-horizon-and-prevent-blindness-are-calling-on-the-thyroid-eye-disease-ted-community-to-put-vision-first/2476979/daily0.7https://crstodayeurope.com/news/aao-and-ascrs-partner-to-host-business-innovation-conferences-beginning-in-2020/2476978/daily0.7https://crstodayeurope.com/news/mynosys-secures-25-million-investment-names-rob-thornhill-as-ceo/2476976/daily0.7https://crstodayeurope.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/daily0.7https://crstodayeurope.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/daily0.7https://crstodayeurope.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/daily0.7https://crstodayeurope.com/news/proqr-announces-positive-topline-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients/2476975/daily0.7https://crstodayeurope.com/news/ocutrx-unveils-orlenz-for-surgery-visualization-technology-in-arwear-headset/2476972/daily0.7https://crstodayeurope.com/news/avedro-announces-schedule-of-events-at-aao/2476970/daily0.7https://crstodayeurope.com/news/canon-usa-to-showcase-eyecare-solutions-at-aao/2476971/daily0.7https://crstodayeurope.com/news/modernizing-medicine-to-display-integrated-ophthalmology-software-suite-at-aao/2476967/daily0.7https://crstodayeurope.com/news/quicksee-handheld-autorefractor-shows-strong-agreement-with-subjective-refraction-measurements/2476968/daily0.7https://crstodayeurope.com/news/eyegate-pharma-completes-randomization-in-pivotal-study/2476965/daily0.7https://crstodayeurope.com/news/ex-shire-ceo-flemming-ornskov-emerges-as-galderma-ceo-after-10b-nestle-spinout/2476966/daily0.7https://crstodayeurope.com/news/orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476963/daily0.7https://crstodayeurope.com/news/injectsense-demonstrates-animal-to-cloud-iop-sensing-pathway-for-glaucoma/2476964/daily0.7https://crstodayeurope.com/news/alcon-to-highlight-acrysof-iq-panoptix-trifocal-iol-launch-and-groundbreaking-iol-data-at-aao/2476961/daily0.7https://crstodayeurope.com/news/eyeris-announces-industry-first-environmentally-conscious-packaging/2476959/daily0.7https://crstodayeurope.com/news/gensight-biologics-reports-evidence-of-gs010-dna-transfer-to-contralateral-eye-of-primates-unilaterally-injected-with-gs010-gene-therapy/2476960/daily0.7https://crstodayeurope.com/news/who-launches-first-world-report-on-vision/2476958/daily0.7https://crstodayeurope.com/news/lensgen-to-review-latest-juvene-iol-results-at-aao/2476954/daily0.7https://crstodayeurope.com/news/navilas-at-aao-2019-laser-is-back-with-digital-guidance-for-posterior-segment-treatments/2476955/daily0.7https://crstodayeurope.com/news/imprimisrx-to-focus-on-investments-in-quality-at-the-2019-aao-meeting/2476951/daily0.7https://crstodayeurope.com/news/zeiss-and-senorics-establish-partnership-focus-on-joint-development-of-sensor-technology/2476952/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-launches-worldwide-connectedbysight-campaign-in-honor-of-world-sight-day/2476949/daily0.7https://crstodayeurope.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476950/daily0.7https://crstodayeurope.com/news/corneagen-raises-37-million-to-advance-development-of-cornea-cell-therapy/2476948/daily0.7https://crstodayeurope.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-new-scientific-and-clinical-analyses-to-be-presented-at-aao/2476944/daily0.7https://crstodayeurope.com/news/allergan-expands-refresh-portfolio-with-new-refresh-relieva-lubricant-eye-drop-product-line/2476943/daily0.7https://crstodayeurope.com/news/teclens-and-servimed-industrial-spa-announce-partnership-to-pursue-fda-approval-for-trans-epithelial-corneal-cross-linking/2476941/daily0.7https://crstodayeurope.com/news/vision-2020-usa-to-hold-annual-world-sight-day-briefing-on-october-17-2019/2476939/daily0.7https://crstodayeurope.com/news/optovue-introduces-netvue-cloud-image-management-solutions-at-aao/2476940/daily0.7https://crstodayeurope.com/news/report-chocolate-may-not-help-your-vision/2476938/daily0.7https://crstodayeurope.com/news/eyewear-and-eyecare-products-are-not-included-in-recently-announced-european-import-duties/2476937/daily0.7https://crstodayeurope.com/news/on-world-sight-day-orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476936/daily0.7https://crstodayeurope.com/news/allergan-to-showcase-late-stage-data-in-amd-and-glaucoma-at-aao-annual-meeting/2476935/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/daily0.7https://crstodayeurope.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/daily0.7https://crstodayeurope.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/daily0.7https://crstodayeurope.com/news/novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence/2476932/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/daily0.7https://crstodayeurope.com/news/ocugen-and-cansinobio-enter-strategic-partnership-for-gene-therapy-co-development-and-manufacturing/2476929/daily0.7https://crstodayeurope.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/daily0.7https://crstodayeurope.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/daily0.7https://crstodayeurope.com/news/bausch-lomb-enters-licensing-agreement-with-intraocular-lens-design-group-tatvum-research/2476928/daily0.7https://crstodayeurope.com/news/ocugen-announces-completion-of-its-merger-with-histogenics-to-create-ocular-gene-therapies-and-biotherapeutics/2476924/daily0.7https://crstodayeurope.com/news/santen-expands-into-surgical-devices-and-publishes-real-world-evidence-in-dry-eye-disease/2476923/daily0.7https://crstodayeurope.com/news/dorc-obtains-510k-clearance-for-launch-of-eva-upgrade-enhancements/2476922/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/daily0.7https://crstodayeurope.com/news/strategies-for-slowing-myopia-progression-in-kids-differ-widely-between-ophthalmologists/2476919/daily0.7https://crstodayeurope.com/news/clinreg-consulting-services-appoints-new-president-and-plans-to-expand-consulting-team/2476920/daily0.7https://crstodayeurope.com/news/nicox-completes-enrolment-of-ncx-4251-phase-2-trial-with-top-line-results-on-track-for-q4-2019/2476918/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/daily0.7https://crstodayeurope.com/news/pharmaceutical-companies-face-steeper-price-cuts-in-china-as-country-expands-drug-bulk-buying-scheme-nationwide/2476915/daily0.7https://crstodayeurope.com/news/haag-streit-uk-announces-the-launch-of-the-ellex-eye-prime/2476912/daily0.7https://crstodayeurope.com/news/carl-zeiss-ag-names-new-president-and-ceo/2476913/daily0.7https://crstodayeurope.com/news/eversight-first-to-offer-preloaded-dmek-in-dorc-tube/2476911/daily0.7https://crstodayeurope.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-at-96-weeks-in-rescue-phase-3-trial-of-gs010-for-the-treatment-of-lhon/2476910/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-rhokiinsa-in-the-european-union/2476906/daily0.7https://crstodayeurope.com/news/cataract-surgery-products-continue-to-be-the-main-single-use-surgical-device-sales-driver/2476905/daily0.7https://crstodayeurope.com/news/sifi-appoints-new-country-manager-for-italy/2476904/daily0.7https://crstodayeurope.com/news/us-house-speaker-nancy-pelosi-introduces-plan-to-permit-price-negotiation-for-some-drugs/2476901/daily0.7https://crstodayeurope.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/daily0.7https://crstodayeurope.com/news/eye-cancer-researchers-at-bascom-palmer-and-sylvester-identify-function-of-key-tumor-suppressor/2476900/daily0.7https://crstodayeurope.com/news/schwind-introduces-new-schwind-atos-femtosecond-laser-with-smartsight/2476899/daily0.7https://crstodayeurope.com/news/compulink-launches-e-commerce-solution-for-its-all-in-one-optometry-ehr-at-vision-expo-west/2476895/daily0.7https://crstodayeurope.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-submits-prior-approval-supplement-to-fda-to-allow-production-of-rocklatan-in-its-athlone-ireland-facility/2476897/daily0.7https://crstodayeurope.com/news/vertical-pharmaceuticals-announces-submission-of-new-drug-application-for-rvl-1201/2476894/daily0.7https://crstodayeurope.com/news/first-international-migs-data-for-the-omni-surgical-system-presented-at-escrs/2476893/daily0.7https://crstodayeurope.com/news/righteye-releases-fully-commercialized-version-of-eyeq-trainer-oculomotor-exercise-program/2476892/daily0.7https://crstodayeurope.com/news/zeiss-and-idoc-partner-to-bring-medical-and-vision-care-products-to-independent-optometrists-nationwide/2476890/daily0.7https://crstodayeurope.com/news/canon-xephilio-oct-a1-device-receives-fda-510k-clearance/2476889/daily0.7https://crstodayeurope.com/news/oculis-announces-appointment-of-leading-ophthalmology-specialists-to-scientific-advisory-board/2476888/daily0.7https://crstodayeurope.com/news/nicox-provides-business-update-and-upcoming-milestones/2476887/daily0.7https://crstodayeurope.com/news/pecaa-and-medical-eyeglass-center-announce-partnership/2476885/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-introduces-tecnis-synergy-iol/2476884/daily0.7https://crstodayeurope.com/news/candida-auris-tied-to-vision-loss-in-case-report/2476883/daily0.7https://crstodayeurope.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent-2/2476882/daily0.7https://crstodayeurope.com/news/zeiss-to-showcase-advancements-in-digital-and-surgical-technology-at-escrs/2476881/daily0.7https://crstodayeurope.com/news/cassini-to-reveal-new-cassini-device-at-the-escrs-in-paris/2476880/daily0.7https://crstodayeurope.com/news/physiol-to-launch-finevision-triumf-trifocal-edof-iol/2476879/daily0.7https://crstodayeurope.com/news/sightglass-vision-to-present-pivotal-clinical-trial-baseline-data-evaluating-novel-lenses-to-control-nearsightedness-in-children/2476876/daily0.7https://crstodayeurope.com/news/alimera-announces-expansion-of-agreement-with-distribution-partner-horus-pharma-to-include-marketing-iluvien-in-benelux-countries/2476878/daily0.7https://crstodayeurope.com/news/genentechs-satralizumab-significantly-reduced-relapse-risk-in-second-positive-phase-3-study-for-neuromyelitis-optica-spectrum-disorder/2476875/daily0.7https://crstodayeurope.com/news/boost-epi-on-corneal-cross-linking-data-to-be-presented-at-escrs/2476874/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-showcases-latest-clinical-data-and-eye-care-solutions-at-escrs-2/2476873/daily0.7https://crstodayeurope.com/news/micropulse-transscleral-laser-therapy-will-be-discussed-in-various-presentations-and-educational-events-at-escrs/2476872/daily0.7https://crstodayeurope.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent/2479535/daily0.7https://crstodayeurope.com/news/registration-now-open-for-international-sports-vision-association-annual-conference/2476869/daily0.7https://crstodayeurope.com/news/eyecare-partners-acquires-nationwide-vision/2476871/daily0.7https://crstodayeurope.com/news/rayner-launching-rayone-trifocal-toric-at-escrs/2476866/daily0.7https://crstodayeurope.com/news/atia-vision-announces-upcoming-presentations-highlighting-modular-presbyopia-correcting-iol-technology/2476867/daily0.7https://crstodayeurope.com/news/the-american-academy-of-ophthalmology-and-verana-health-launch-verana-practice-insights-to-innovate-patient-care/2476864/daily0.7https://crstodayeurope.com/news/alcon-launches-new-planning-software-and-patient-interface-for-the-wavelight-refractive-suite/2476863/daily0.7https://crstodayeurope.com/news/wills-eye-hospital-named-1-ophthalmology-training-program-in-america/2479536/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/daily0.7https://crstodayeurope.com/news/corneat-vision-completes-preclinical-phase-for-synthetic-cornea-and-scleral-patch/2479538/daily0.7https://crstodayeurope.com/news/cigna-rolls-out-new-plan-to-fully-cover-multi-million-dollar-gene-therapies/2479539/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-evo-icl-clinical-program-for-its-16th-annual-surgical-experts-summit-in-paris/2479541/daily0.7https://crstodayeurope.com/news/mst-innovations-introduces-the-scleral-iol-fixation-solutions-pack/2476857/daily0.7https://crstodayeurope.com/news/eyecare-partners-completes-acquisition-of-associated-retinal-consultants/2476858/daily0.7https://crstodayeurope.com/news/istar-medical-announces-eur-40-million-series-c-financing/2479542/daily0.7https://crstodayeurope.com/news/zeiss-showcases-new-cirrus-6000-oct-system-at-euretina/2479543/daily0.7https://crstodayeurope.com/news/genentech-to-present-pivitol-data-for-satralizumab-in-neuromyelitis-optica-spectrum-disorder/2476853/daily0.7https://crstodayeurope.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-strategic-alliance-agreement-with-asian-eye-institute/2476850/daily0.7https://crstodayeurope.com/news/sight-sciences-raises-56m-to-lead-the-development-of-migs-market-and-procedure-based-dry-eye-market/2476848/daily0.7https://crstodayeurope.com/news/alcon-names-carla-mack-od-global-head-of-professional-affairs-for-vision-care/2476847/daily0.7https://crstodayeurope.com/news/alimera-sciences-launches-iluvien-in-germany-for-noninfectious-uveitis/2476846/daily0.7https://crstodayeurope.com/news/ziemer-to-present-its-new-aquariuz-ablation-laser-at-escrs-in-paris/2476841/daily0.7https://crstodayeurope.com/news/kowas-submits-ind-application-to-the-fda-to-begin-phase-2-study-of-ripasudil-hydrochloride-hydrate/2476842/daily0.7https://crstodayeurope.com/news/horus-pharma-launches-neovis-total-multi-for-dry-eye-in-new-size/2476843/daily0.7https://crstodayeurope.com/news/santen-announces-topline-data-for-de-128-microshunt-demonstrating-reductions-in-iop-and-medication-use-in-patients-with-glaucoma/2476840/daily0.7https://crstodayeurope.com/news/altered-visual-processing-a-nonverbal-marker-of-autism/2476838/daily0.7https://crstodayeurope.com/news/oculus-release-myopia-master-for-myopia-management/2476839/daily0.7https://crstodayeurope.com/news/lenstec-completes-fda-trial-for-sbl-3-iol/2476837/daily0.7https://crstodayeurope.com/news/japan-conducts-worlds-1st-transplant-with-ips-cells-for-corneal-disease/2476836/daily0.7https://crstodayeurope.com/news/topcon-announces-the-release-of-harmony-into-the-emea-region/2476835/daily0.7https://crstodayeurope.com/news/hoya-vision-care-plans-25-million-dollar-expansion-of-u-s-lab/2476833/daily0.7https://crstodayeurope.com/news/now-optics-names-two-women-to-its-executive-leadership-team/2476834/daily0.7https://crstodayeurope.com/news/okyo-pharma-announces-potent-anti-inflammatory-effects-of-ok-113-in-a-mouse-model-of-dry-eye-disease/2476830/daily0.7https://crstodayeurope.com/news/righteye-new-research-demonstrates-reliability-of-eye-tracking-data-to-identify-and-measure-severity-of-traumatic-brain-injuries/2476832/daily0.7https://crstodayeurope.com/news/oculus-to-releases-new-features-for-the-corvis-st-at-escrs/2476829/daily0.7https://crstodayeurope.com/news/amblyoplay-now-offers-its-vision-therapy-solution-for-lazy-eye-in-the-united-states/2476828/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-fda-ide-clinical-study-approval/2476825/daily0.7https://crstodayeurope.com/news/topcon-launches-the-maestro2-with-automated-octa/2476826/daily0.7https://crstodayeurope.com/news/alcon-introduces-acrysof-iq-panoptix-trifocal-iol-in-the-us-the-first-and-only-fda-approved-trifocal-lens/2476827/daily0.7https://crstodayeurope.com/news/oklahoma-judge-orders-johnson-johnson-to-pay-572-million-in-bellwether-opioid-case/2476824/daily0.7https://crstodayeurope.com/news/new-accessible-products-hotline-to-offer-advice-on-products-for-blind-or-visually-impaired/2476823/daily0.7https://crstodayeurope.com/news/vsy-biotechnologys-rotaryjet-preloaded-injector-has-been-registered-by-the-european-patent-institute/2476820/daily0.7https://crstodayeurope.com/news/quantel-medical-announces-acquisition-of-optotek-medical/2476821/daily0.7https://crstodayeurope.com/news/new-world-medical-launches-ahmed-clearpath-glaucoma-drainage-device/2476814/daily0.7https://crstodayeurope.com/news/trump-administration-to-appeal-ruling-barring-proposed-drug-price-disclosure-policy/2476816/daily0.7https://crstodayeurope.com/news/orbis-celebrates-new-data-showing-a-91-reduction-in-populations-at-risk-of-blinding-trachoma-in-endemic-areas/2479544/daily0.7https://crstodayeurope.com/news/examining-the-role-of-vitamin-b3-supplementation-in-reducing-and-preventing-retinal-cell-damage-caused-by-glaucoma/2476813/daily0.7https://crstodayeurope.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/daily0.7https://crstodayeurope.com/news/migs-devices-continue-to-expand-use-of-glaucoma-surgery/2476811/daily0.7https://crstodayeurope.com/news/american-journal-of-ophthalmology-publishes-review-highlighting-lack-of-treatments-for-active-thyroid-eye-disease-ted/2476809/daily0.7https://crstodayeurope.com/news/alcon-to-launch-precision1-daily-disposable-contact-lenses/2476810/daily0.7https://crstodayeurope.com/news/trial-of-tele-ophthalmology-system-at-regional-health-board-in-scotland-shows-promising-results/2476808/daily0.7https://crstodayeurope.com/news/course-of-stargardt-disease-varies-between-siblings/2476807/daily0.7https://crstodayeurope.com/news/maui-jim-and-vsp-global-expand-relationship-to-include-maui-jim-inside-the-vsp-formulary/2479547/daily0.7https://crstodayeurope.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/daily0.7https://crstodayeurope.com/news/cloud-based-telemedicine-platform-may-cut-unnecessary-ophthalmology-referrals/2476804/daily0.7https://crstodayeurope.com/news/prevent-blindness-creates-new-diabetes-and-the-eyes-educational-resource/2476805/daily0.7https://crstodayeurope.com/news/oculus-introduces-pentacam-axl-wave/2479548/daily0.7https://crstodayeurope.com/news/international-sports-vision-association-launches-dynamic-visual-skills-for-sports/2476801/daily0.7https://crstodayeurope.com/news/fda-does-not-approve-kala-pharmaceuticals-nda-for-dry-eye-disease-candidate/2476799/daily0.7https://crstodayeurope.com/news/bausch-health-ceo-big-pharma-will-survive-us-drug-regulations/2476798/daily0.7https://crstodayeurope.com/news/ash-attia-becomes-news-ceo-of-bionic-vision-technologies/2476797/daily0.7https://crstodayeurope.com/news/glaukos-announces-agreement-to-buy-avedro-in-all-stock-deal/2479551/daily0.7https://crstodayeurope.com/news/optronics-introduces-microcast-pro-medical-grade-microscope-video-camera-platform/2476796/daily0.7https://crstodayeurope.com/news/national-center-for-childrens-vision-and-eye-health-at-prevent-blindness-receives-renewed-grant/2476794/daily0.7https://crstodayeurope.com/news/sight-sciences-hires-several-industry-executives-to-drive-growth/2476793/daily0.7https://crstodayeurope.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/daily0.7https://crstodayeurope.com/news/study-yellow-lens-glasses-dont-improve-drivers-night-vision/2476789/daily0.7https://crstodayeurope.com/news/vsy-biotechnologys-rotaryjet-preloaded-injector-registered-by-the-european-patent-institute/2476791/daily0.7https://crstodayeurope.com/news/forbes-will-your-iphones-dark-mode-save-your-eyes/2476786/daily0.7https://crstodayeurope.com/news/harrow-health-forms-stowe-pharmaceuticals-subsidiary-to-develop-anti-microbial-ophthalmic-and-otic-therapeutics/2479553/daily0.7https://crstodayeurope.com/news/staar-surgical-announces-submission-of-presbyopia-clinical-trial-data/2479554/daily0.7https://crstodayeurope.com/news/us-outlines-plans-to-allow-importation-of-certain-prescription-drugs-from-canada-other-countries/2479556/daily0.7https://crstodayeurope.com/news/acuity-eyecare-group-enters-texas-market-with-multiple-acquisitions/2476785/daily0.7https://crstodayeurope.com/news/clearside-biomedical-announces-multiple-presentations-delivered-at-the-asrs-annual-meeting/2479557/daily0.7https://crstodayeurope.com/news/ray-ban-maker-agrees-to-buy-grandvision-for-8-billion/2479558/daily0.7https://crstodayeurope.com/news/schwind-more-than-6-million-treatments-with-amaris-eximer-laser/2479559/daily0.7https://crstodayeurope.com/news/bausch-lomb-initiates-first-clinical-trial-for-technolas-teneo-excimer-laser-in-the-united-states/2479560/daily0.7https://crstodayeurope.com/news/biotime-announces-name-change-to-lineage-cell-therapeutics/2479562/daily0.7https://crstodayeurope.com/news/johnson-johnson-vision-launches-new-surgical-vision-experience-center-at-the-johnson-johnson-institute-in-jacksonville/2476784/daily0.7https://crstodayeurope.com/news/cms-issues-proposed-2020-asc-payment-rule/2479563/daily0.7https://crstodayeurope.com/news/doctor-alexa-will-see-you-now-is-amazon-primed-to-come-to-your-rescue/2476782/daily0.7https://crstodayeurope.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology/2476783/daily0.7https://crstodayeurope.com/news/wills-eye-takes-top-honors-for-excellence-in-patient-care-in-annual-best-hospitals-list/2476781/daily0.7https://crstodayeurope.com/news/pfizer-to-combine-upjohn-off-patent-drug-business-with-mylan-into-new-company/2476776/daily0.7https://crstodayeurope.com/news/phrma-comes-out-against-us-senate-drug-pricing-bill/2476770/daily0.7https://crstodayeurope.com/news/novartis-mundipharma-ink-partnership-to-enhance-access-to-three-asian-countries-to-established-medicine-brands-for-glaucoma-and-external-eye-diseases/2476771/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/daily0.7https://crstodayeurope.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-early-assignment-of-permanent-and-specific-j-code-for-yutiq/2476769/daily0.7https://crstodayeurope.com/news/omeros-omidria-receives-product-specific-j-code-from-cms/2476766/daily0.7https://crstodayeurope.com/news/oyster-point-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/2476763/daily0.7https://crstodayeurope.com/news/polyactiva-completes-recruitment-in-phase-1-glaucoma-implant-safety-study/2476759/daily0.7https://crstodayeurope.com/news/ocuphire-pharma-raises-over-5-million-to-complete-late-phase-2-clinical-trials-for-ophthalmic-disorders/2476760/daily0.7https://crstodayeurope.com/news/alcon-launches-new-website-to-educate-patients-on-lasik-and-contoura-vision/2476758/daily0.7https://crstodayeurope.com/news/eversight-awards-2019-eye-vision-research-grants/2476757/daily0.7https://crstodayeurope.com/news/glaukos-announces-global-licensing-agreement-with-intratus/2476756/daily0.7https://crstodayeurope.com/news/study-female-ophthalmology-residents-perform-fewer-procedures/2476755/daily0.7https://crstodayeurope.com/news/bausch-lomb-introduces-23-gauge-bi-blade-dual-port-vitrectomy-cutter-for-the-stellaris-elite-vision-enhancement-system/2476752/daily0.7https://crstodayeurope.com/news/new-software-update-expands-capabilities-of-the-od-os-navilas-577s/2476754/daily0.7https://crstodayeurope.com/news/eye-specialist-works-to-prevent-motor-vehicle-related-traumatic-eye-injuries/2476751/daily0.7https://crstodayeurope.com/news/altaire-pharmaceuticals-expands-voluntary-recall-of-multiple-otc-ophthalmic-products/2476747/daily0.7https://crstodayeurope.com/news/market-scope-advancing-technology-drives-ophthalmic-or-microscope/2476746/daily0.7https://crstodayeurope.com/news/vision-source-wins-2-million-contract-for-achievements-in-value-based-care/2476745/daily0.7https://crstodayeurope.com/news/eye-surgery-associates-enters-strategic-partnership-with-eyecare-services-partners/2476743/daily0.7https://crstodayeurope.com/news/nidek-launches-lpm-low-power-mode-for-ylc-500-vixi/2476744/daily0.7https://crstodayeurope.com/news/sun-pharma-introduces-access-program-for-patients-prescribed-xelpros-in-the-us/2476741/daily0.7https://crstodayeurope.com/news/medicel-launches-first-2-in-1-lens-injection-system/2476740/daily0.7https://crstodayeurope.com/news/fda-accepts-allergans-nda-for-bimatoprost-sustained-release-in-patients-with-open-angle-glaucoma-or-ocular-hypertension/2476739/daily0.7https://crstodayeurope.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/daily0.7https://crstodayeurope.com/news/nicox-announces-completion-of-enrollment-in-ncx-470-phase-2-clinical-study-with-topline-results-on-track-for-early-4q-2019/2476734/daily0.7https://crstodayeurope.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/daily0.7https://crstodayeurope.com/news/clerio-vision-acquires-manufacturer-of-extreme-h2o-contact-lenses/2476732/daily0.7https://crstodayeurope.com/news/foundation-fighting-blindness-appoints-judy-taylor-vice-president-development/2476733/daily0.7https://crstodayeurope.com/news/zeiss-marks-milestone-for-its-new-north-america-high-tech-site-in-dublin-california/2476730/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-christopher-white-as-senior-vice-president-head-of-business-and-corporate-development/2476725/daily0.7https://crstodayeurope.com/news/prism-vision-group-announces-launch-of-new-brand/2476726/daily0.7https://crstodayeurope.com/news/childrens-hospital-los-angeles-has-treated-14-patients-with-retinal-degeneration-using-gene-therapy/2476727/daily0.7https://crstodayeurope.com/news/any-microvascular-disease-a-risk-factor-for-limb-amputation/2476728/daily0.7https://crstodayeurope.com/news/us-scraps-proposal-to-curb-drug-rebates-paid-to-pharmacy-benefit-managers/2476729/daily0.7https://crstodayeurope.com/news/market-scope-booming-demand-surgical-planning-integration-drive-growth-in-ophthalmic-diagnostic-market/2476723/daily0.7https://crstodayeurope.com/news/omeros-announces-agreement-with-fda-on-primary-endpoint-for-narsoplimab-bla-in-stem-cell-transplant-associated-tma/2476724/daily0.7https://crstodayeurope.com/news/one-week-left-to-submit-nominations-for-owl-awards/2476721/daily0.7https://crstodayeurope.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/daily0.7https://crstodayeurope.com/news/horizon-therapeutics-submits-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease/2476716/daily0.7https://crstodayeurope.com/news/uk-to-test-subscription-style-payment-model-in-effort-to-spur-development-of-new-antibiotics/2476717/daily0.7https://crstodayeurope.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins/2476714/daily0.7https://crstodayeurope.com/news/wize-pharma-enters-joint-venture-with-cannabics-pharmaceuticals-to-develop-cannabinoid-ophthalmic-treatments/2476713/daily0.7https://crstodayeurope.com/news/us-judge-invalidates-rule-requiring-drugmakers-to-disclose-price-of-medicines-in-tv-ads/2479564/daily0.7https://crstodayeurope.com/news/roche-spark-push-back-takeover-deadline-in-4-3-billion-deal/2479565/daily0.7https://crstodayeurope.com/news/clearside-biomedical-announces-license-agreement-with-aura-biosciences-for-suprachoroidal-space-microinjector/2479566/daily0.7https://crstodayeurope.com/news/nicox-receives-3-million-milestone-payment-from-eyevance-for-zerviate-in-the-us/2479567/daily0.7https://crstodayeurope.com/news/aerie-pharmaceuticals-completes-enrollment-of-the-netarsudil-phase-2-clinical-trial-in-japan-ahead-of-schedule/2479568/daily0.7https://crstodayeurope.com/news/zeiss-receives-fda-clearance-for-clarus-700-ultra-widefield-imaging-device/2479571/daily0.7https://crstodayeurope.com/news/eye-drops-sold-at-walmart-walgreens-recalled-because-they-may-not-be-sterile/2479572/daily0.7https://crstodayeurope.com/news/eyepoint-pharmaceuticals-announces-us-commercialization-of-dexycu/2479573/daily0.7https://crstodayeurope.com/news/sifi-announces-expansion-in-the-french-market-with-acquisition-of-dacudoses-and-novoptine/2479574/daily0.7https://crstodayeurope.com/news/eyesouth-establishes-presence-in-alabama-through-affiliation-with-montgomery-eye-physicians/2476711/daily0.7https://crstodayeurope.com/news/promedica-international-and-dr-agarwals-eye-hospitals-form-strategic-alliance-2/2476709/daily0.7https://crstodayeurope.com/news/nicox-signs-agreement-for-ncx-4251-in-china-with-ocumension-therapeutics-for-up-to-e12-million/2476710/daily0.7https://crstodayeurope.com/news/hoya-surgical-optics-obtained-ce-mark-for-nanex-multisert-iol-delivery-system/2476708/daily0.7https://crstodayeurope.com/news/novartis-completes-acquisition-of-xiidra-bolstering-ophthalmic-portfolio/2476707/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-commercial-launch-of-dextenza/2476704/daily0.7https://crstodayeurope.com/news/low-cost-retinal-scanner-could-help-prevent-blindness-worldwide/2476705/daily0.7https://crstodayeurope.com/news/fda-approves-first-treatment-for-neuromyelitis-optica-spectrum-disorder/2476703/daily0.7https://crstodayeurope.com/news/vsp-global-enters-into-definitive-agreement-to-acquire-visionworks/2476699/daily0.7https://crstodayeurope.com/news/blephex-asserts-claims-of-patent-infringement-and-false-advertising-against-myco-industries/2476700/daily0.7https://crstodayeurope.com/news/visual-cortical-prosthesis-is-tested-at-baylor-college-of-medicine/2476698/daily0.7https://crstodayeurope.com/news/nusight-medical-announces-issuance-of-u-s-patent-covering-the-nulids-system-for-treating-dry-eye-disease/2476697/daily0.7https://crstodayeurope.com/news/alpineinvestors-to-make-strategic-growth-investments-in-ohio-eye-care-businesses/2476694/daily0.7https://crstodayeurope.com/news/alan-r-morse-jd-phd-vision-and-healthcare-services-innovator-will-retire-as-president-ceo-of-lighthouse-guild/2476695/daily0.7https://crstodayeurope.com/news/promedica-international-and-dr-agarwals-eye-hospitals-form-strategic-alliance/2476696/daily0.7https://crstodayeurope.com/news/aldeyra-therapeutics-phase-3-solace-trial-fails-to-meet-primary-endpoint-in-noninfectious-anterior-uveitis/2476691/daily0.7https://crstodayeurope.com/news/new-research-suggests-glaucoma-screening-could-save-three-million-years-of-blindness-in-china/2476692/daily0.7https://crstodayeurope.com/news/outdoor-exercise-reduces-progression-of-common-vision-issue-in-children/2476693/daily0.7https://crstodayeurope.com/news/new-cpt-code-for-automated-point-of-care-retinal-imaging/2476690/daily0.7https://crstodayeurope.com/news/vsy-biotechnology-is-now-accepting-applications-for-the-ophthalmology-star-awards/2476689/daily0.7https://crstodayeurope.com/news/dompe-announces-first-patient-enrolled-in-phase-2b-clinical-trial-investigating-dry-eye-disease-drug-candidate/2476687/daily0.7https://crstodayeurope.com/news/new-research-to-explore-how-to-help-adults-with-vision-loss-continue-to-drive-safely/2476688/daily0.7https://crstodayeurope.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/daily0.7https://crstodayeurope.com/news/generic-drug-maker-alembic-pharmaceuticals-receives-fda-approval-for-bromfenac-ophthalmic-solution-0-09/2476685/daily0.7https://crstodayeurope.com/news/avellino-labs-founder-gene-lee-receives-2019-ellis-island-medal-of-honor/2476683/daily0.7https://crstodayeurope.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-receives-fda-approval-of-supplemental-nda-for-dextenza-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery/2476680/daily0.7https://crstodayeurope.com/news/coburn-technologies-launches-brand-new-consumables-e-commerce-website/2476681/daily0.7https://crstodayeurope.com/news/carl-zeiss-meditec-announces-investment-in-clinical-stage-migs-device-maker-microoptx/2476679/daily0.7https://crstodayeurope.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/daily0.7https://crstodayeurope.com/news/righteye-usa-baseball-and-optometrists-team-up-to-improve-players-athletic-abilities-through-sports-vision/2476677/daily0.7https://crstodayeurope.com/news/eyecarelive-unveils-enhanced-responsible-telemedicine-platform-for-optometry-and-ophthalmology/2476674/daily0.7https://crstodayeurope.com/news/alimeras-iluvien-receives-positive-nice-recommendation-for-noninfectious-posterior-uveitis/2476675/daily0.7https://crstodayeurope.com/news/ocutech-adds-3x-and-5-5x-power-options-for-the-falcon-autofocus-bioptic/2476672/daily0.7https://crstodayeurope.com/news/the-vision-council-files-joint-letter-in-opposition-of-china-301-tariffs-will-testify-on-thursday/2476669/daily0.7https://crstodayeurope.com/news/new-survey-highlights-growing-insurance-problem-that-delays-sight-saving-care/2476670/daily0.7https://crstodayeurope.com/news/uks-first-transform-inlay-procedure-performed-by-sheraz-daya-md/2476668/daily0.7https://crstodayeurope.com/news/harrow-health-to-locate-headquarters-in-nashville-tennessee/2476667/daily0.7https://crstodayeurope.com/news/novabay-pharmaceuticals-appoints-justin-hall-president-and-ceo-and-jason-raleigh-cfo/2476666/daily0.7https://crstodayeurope.com/news/compulink-showcases-new-user-interface-for-its-optometry-smart-ehr-at-aoa-optometrys-meeting/2476664/daily0.7https://crstodayeurope.com/news/be-the-match-biotherapies-and-trakcel-partner-to-standardize-cell-and-gene-therapy-supply-chain-solutions/2476662/daily0.7https://crstodayeurope.com/news/research-shows-gene-therapy-may-restore-visual-function-for-people-with-night-blindness/2476663/daily0.7https://crstodayeurope.com/news/eyepromise-introduces-screen-shield-pro-all-natural-eye-vitamin-for-screen-time-protection-for-adults/2476661/daily0.7https://crstodayeurope.com/news/santen-publishes-new-data-in-glaucoma-and-dry-eye-drug-candidates/2476660/daily0.7https://crstodayeurope.com/news/house-subcommittee-urges-ftc-to-modernize-contact-lens-verification-process/2476657/daily0.7https://crstodayeurope.com/news/us-drugmakers-file-lawsuit-against-rule-requiring-drug-prices-in-tv-ads/2476658/daily0.7https://crstodayeurope.com/news/glaucoma-drugs-continue-to-battle-for-market-share/2476655/daily0.7https://crstodayeurope.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/daily0.7https://crstodayeurope.com/news/amarantus-announces-issuance-of-us-patent-covering-manf-treatment-of-wolframs-syndrome-retinitis-pigmentosa-and-glaucoma/2476653/daily0.7https://crstodayeurope.com/news/first-subject-enrolled-in-large-trial-to-confirm-safety-and-efficacy-of-dry-eye-treatment-device-tearcare/2476650/daily0.7https://crstodayeurope.com/news/brits-in-the-dark-over-eye-health-according-to-orbis-uk/2476651/daily0.7https://crstodayeurope.com/news/neuro-optometric-rehabilitation-association-and-vestibular-disorders-asociation-offer-new-educational-resource-on-the-vestibular-vision-connection/2476649/daily0.7https://crstodayeurope.com/news/aerpio-initiates-phase-1b-clinical-trial-of-topical-ocular-formulation-of-akb-9778-for-primary-open-angle-glaucoma/2476645/daily0.7https://crstodayeurope.com/news/ocusoft-introduces-new-ocusoft-lid-scrub-allergy-eyelid-treatment-for-red-itchy-allergy-eyes/2476646/daily0.7https://crstodayeurope.com/news/our-tears-could-one-day-tell-us-if-we-have-glaucoma/2476643/daily0.7